Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

ARC-520

Oligonucleotide (siRNA) · developed by Arrowhead Pharmaceuticals

Phase 2 Most advanced trial (none active)
ARWR Developer
2 Registered trials

What is ARC-520?

ARC-520 is an investigational small interfering RNA (siRNA) oligonucleotide studied in chronic hepatitis B.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Oligonucleotide (siRNA)
Therapy area
Infectious disease
Developer
Arrowhead Pharmaceuticals (ARWR)
Also in trials of
ICLR
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02604199 Phase 2 Hepatitis B Terminated ARWR
NCT02065336 Phase 2 Hepatitis B, Chronic Terminated ARWR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hepatitis BHepatitis B, Chronic

More from Arrowhead Pharmaceuticals

Follow ARWR, the company behind ARC-520

See ARWR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ARWR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.